2026-526612-36-00Not yet recruitingPhase 4
A study on stopping versus continuing beta-blockers in patients with hypertrophic cardiomyopathy treated with mavacamten
Source: EU CTIS (euclinicaltrials.eu) · Last updated 13 Oct 2026
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- First submitted
- 12 Aug 2026
- Start date
- 1 Jan 2027
- Lead sponsor
- Ziekenhuis Oost Limburg
- Diseases
- Hypertrophic cardiomyopathy
- EU CT number
- 2026-526612-36-00
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 90
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with obstructive hypertrophic cardiomyopathy who are treated with mavacamten, to compare stopping versus continuing beta-blockers.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Obstructive hypertrophic cardiomyopathy.
- Earlier treatment
- Treated with mavacamten. The record also mentions beta-blockers.
Main reasons for not taking part
- Healthy volunteers cannot join.
Read by machine on 9 Nov 2026.
Sites (4)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universitair Ziekenhuis Antwerpen | Edegem | Belgium | Not yet recruiting |
| Ziekenhuis Oost-Limburg | Genk | Belgium | Not yet recruiting |
| JESSA Ziekenhuis | Hasselt | Belgium | Not yet recruiting |
| Cliniques Universitaires Saint-Luc | Sint-Lambrechts-Woluwe | Belgium | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.